Thank you to @skopetz of @MDAndersonNews for stopping by to discuss exciting results from the BREAKWATER trial of encorafenib plus cetuximab and chemotherapy in CRC. Check back ontomorrow for a clip from our interview! @ASCO #GI25 #medtwitter #oncology
#GI25 #medtwitter #oncology